• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms.

作者信息

Bouligny Ian M, Montalban-Bravo Guillermo, Sasaki Koji, Daver Naval, Jabbour Elias, Alvarado Yesid, DiNardo Courtney D, Ravandi Farhad, Borthakur Gautam, Pemmaraju Naveen, Kadia Tapan, Masarova Lucia, Takahashi Koichi, Andreeff Michael, Bazinet Alexandre, Yang Hui, Kanagal Rashmi, Pierce Sherry, Meyer Meghan, Huang Xuelin, Garcia-Manero Guillermo

机构信息

The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd., Houston, TX, 77030, USA.

The University of Texas MD Anderson Cancer Center, Department of Hematopathology, 1515 Holcombe Blvd., Houston, TX, 77030, USA.

出版信息

Leukemia. 2025 Feb;39(2):524-528. doi: 10.1038/s41375-024-02457-7. Epub 2024 Nov 17.

DOI:10.1038/s41375-024-02457-7
PMID:39551874
Abstract
摘要

相似文献

1
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms.一项关于伊匹木单抗、纳武单抗、或伊匹木单抗与纳武单抗联合使用（伴或不伴阿扎胞苷）治疗复发或难治性骨髓增生异常肿瘤的II期试验。
Leukemia. 2025 Feb;39(2):524-528. doi: 10.1038/s41375-024-02457-7. Epub 2024 Nov 17.
2
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.伊匹木单抗、纳武单抗和本妥昔单抗联合疗法用于复发或难治性霍奇金淋巴瘤患者：一项开放标签、多中心、1/2期试验的1期结果
Lancet Haematol. 2020 Sep;7(9):e660-e670. doi: 10.1016/S2352-3026(20)30221-0.
3
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome.阿扎胞苷联合伊匹木单抗、纳武单抗或伊匹木单抗与纳武单抗用于既往未治疗的骨髓增生异常综合征的II期试验。
Haematologica. 2025 Jul 1;110(7):1628-1633. doi: 10.3324/haematol.2024.286559. Epub 2025 Feb 20.
4
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.纳武利尤单抗联合伊匹单抗治疗儿童和青年复发性/难治性实体瘤的 I/II 期试验：儿童肿瘤学组 ADVL1412 研究。
Clin Cancer Res. 2022 Dec 1;28(23):5088-5097. doi: 10.1158/1078-0432.CCR-22-2164.
5
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.纳武利尤单抗联合伊匹单抗对比纳武利尤单抗单药治疗头颈部复发或转移性鳞状细胞癌的疗效和安全性：Ⅱ期 CheckMate 714 随机临床试验。
JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147.
6
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.尼伏鲁单抗或尼伏鲁单抗联合伊匹单抗治疗复发恶性胸膜间皮瘤（IFCT-1501 MAPS2）：一项多中心、开放标签、随机、非对照、2 期临床试验。
Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16.
7
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).纳武利尤单抗联合或不联合伊匹单抗联合立体定向体部放疗治疗难治性转移性胰腺癌的随机 II 期研究（CheckPAC）。
J Clin Oncol. 2022 Sep 20;40(27):3180-3189. doi: 10.1200/JCO.21.02511. Epub 2022 Apr 27.
8
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.纳武利尤单抗联合疫苗治疗伊匹单抗难治或初治黑色素瘤的安全性、有效性和生物标志物。
J Clin Oncol. 2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802. Epub 2013 Oct 21.
9
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.OpACIN-neo 研究：新辅助伊匹单抗联合纳武利尤单抗治疗 III 期宏观黑色素瘤的最佳联合剂量方案选择：一项多中心、Ⅱ 期、随机、对照试验
Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31.
10
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.纳武利尤单抗治疗伊匹单抗治疗后进展的转移性黑色素瘤患者的 I/II 期研究。
Cancer Immunol Res. 2016 Apr;4(4):345-53. doi: 10.1158/2326-6066.CIR-15-0193. Epub 2016 Feb 12.

引用本文的文献

1
Comparative Analysis of the TCR Repertoire in Bone Marrow CD8 T Cells From Patients With Acute Myeloid Leukemia, Myelodysplastic Neoplasms, and Chronic Myelomonocytic Leukemia.急性髓系白血病、骨髓增生异常综合征和慢性粒单核细胞白血病患者骨髓CD8 T细胞中TCR库的比较分析
Eur J Immunol. 2025 Jun;55(6):e51796. doi: 10.1002/eji.202551796.
2
The Emerging Role of CD8 T Cells in Shaping Treatment Outcomes of Patients with MDS and AML.CD8 T细胞在塑造骨髓增生异常综合征和急性髓系白血病患者治疗结局中的新作用
Cancers (Basel). 2025 Feb 22;17(5):749. doi: 10.3390/cancers17050749.

本文引用的文献

1
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.评估接受免疫治疗的多种晚期癌症患者的肿瘤突变负担和结局。
JAMA Netw Open. 2023 May 1;6(5):e2311181. doi: 10.1001/jamanetworkopen.2023.11181.
2
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.2023年国际工作组关于高危骨髓增生异常综合征修订反应标准的共识提案。
Blood. 2023 Apr 27;141(17):2047-2061. doi: 10.1182/blood.2022018604.
3
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.
靶向骨髓增生异常综合征和急性髓系白血病中的PD-1/PD-L1通路。
Exp Hematol Oncol. 2022 Mar 2;11(1):11. doi: 10.1186/s40164-022-00263-4.
4
Genomic instability, inflammatory signaling and response to cancer immunotherapy.基因组不稳定性、炎症信号传导与癌症免疫治疗反应
Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188661. doi: 10.1016/j.bbcan.2021.188661. Epub 2021 Nov 17.
5
The emerging role of immune checkpoint based approaches in AML and MDS.基于免疫检查点的方法在急性髓系白血病和骨髓增生异常综合征中的新作用。
Leuk Lymphoma. 2018 Apr;59(4):790-802. doi: 10.1080/10428194.2017.1344905. Epub 2017 Jul 6.
6
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.纳武利尤单抗作为程序性死亡受体-1（PD-1）抑制剂用于肿瘤的靶向免疫治疗。
J Cancer. 2017 Feb 10;8(3):410-416. doi: 10.7150/jca.17144. eCollection 2017.
7
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.低甲基化药物治疗失败后低危和中危-1骨髓增生异常综合征患者的结局：代表骨髓增生异常综合征临床研究联盟的报告
Cancer. 2015 Mar 15;121(6):876-82. doi: 10.1002/cncr.29145. Epub 2014 Nov 19.
8
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.低甲基化剂治疗可增强骨髓增生异常综合征中 PD-L1、PD-L2、PD-1 和 CTLA4 的表达。
Leukemia. 2014 Jun;28(6):1280-8. doi: 10.1038/leu.2013.355. Epub 2013 Nov 25.
9
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.低甲基化剂治疗骨髓增生异常综合征失败。
Semin Oncol. 2011 Oct;38(5):682-92. doi: 10.1053/j.seminoncol.2011.04.011.
10
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.地西他滨治疗失败的骨髓增生异常综合征患者的结局。
Cancer. 2010 Aug 15;116(16):3830-4. doi: 10.1002/cncr.25247.